Cargando…
The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa
BACKGROUND: MammaPrint (MP) has been applied in South Africa (SA) for decision-making in early-stage hormone receptor-positive breast cancer since 2006. The cost-impact of MP in SA has not been assessed. AIM: To assess different MP testing strategies for cost-minimization in early-stage breast carci...
Autores principales: | Myburgh, Ettienne J., de Jager, Josephus J., Murray, Elizabeth, Grant, Kathleen A., Kotze, Maritha J., de Klerk, Hermanus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259301/ https://www.ncbi.nlm.nih.gov/pubmed/34217105 http://dx.doi.org/10.1016/j.breast.2021.05.010 |
Ejemplares similares
-
RE: The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa
por: Mansani, Fabio Postiglione, et al.
Publicado: (2022) -
Prognostic Value of MammaPrint(®) in Invasive Lobular Breast Cancer
por: Beumer, Inès J., et al.
Publicado: (2016) -
Equivalence of MammaPrint array types in clinical trials and diagnostics
por: Beumer, Inès, et al.
Publicado: (2016) -
The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint
por: Xin, Ling, et al.
Publicado: (2017) -
MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial
por: Soliman, Hatem, et al.
Publicado: (2020)